Determining operability in patients with aortic valve disease is dependent on two major factors: The extent of damage induced by strain on the myocardium from stenotic and regurgitant lesions and technical and anatomical considerations related to the surgical procedure itself. The decision to intervention. Indications recommend performing corrective procedures before establishment of severe myocardial damage. Thus the treating physician may believe that it is too late to refer a co-morbidities, and when myocardial contractile reserve is poor.
(AS) is currently the most common cause of AS in adults and the most frequent reason for aortic valve replacement (AVR) in these patients. Its incidence is on the rise since this pathology is a disease of ageing and the population is getting older. 1 The natural history of AS has shown that in the absence of surgical management the patient develops progressive invalidating symptoms of syncope and angina. The mortality -tively, from congestive heart failure. 2 Indication for surgery arises when the severity of the ste-0.6 cm²/m² body surface area) or the patient becomes symptomatic. 3 Conventional surgical AVR is the reference treatment and is performed under cardiopulmonary bypass, cardiac arrest and aortic cross-clamping. The native cusps are excised and a prosthesis is sutured into the aortic annulus replacing the native valve (Figure 1 ).
Isolated AVR carries an average 30 day mortality of 3.8±1.5%. 4 AVR is the "gold standard" treatment for symptomatic aortic stenosis and has shown to improve outcome and survival. Following AVR and removal of the obstruction to rapidly improves in part because the ventricle has been preconditioned to generate higher pressures. Thus, there are few contraindications to valve replacement for severe aortic stenosis when left ventricular function is not depressed. 5 Moreover, the indications for intervention have been revised to perform corrective procedures before establishment of severe myocardial damage and according to some authors even prior to onset of symptoms. 6 A multivariate analysis of almost 6,000 patients having AVR, showed mortality were age≥80 years, NYHA class≥III, EF≤30% associated with previous MI, emergent AVR and concomitant coronary artery bypass graft (CABG) surgery. 7
Limits related to age:
Cardiologists are reluctant to refer elderly and high-risk patients for AVR. Age was a recurrent factor for refusing surgery for 31.8% of patients with AS of the Euro Heart Survey on Valvular Heart Disease 8 and 62% of patients with AS in another study from the USA. 9 Advanced age is an important predictor of operative risk and survival in cardiac surgery. It has repeatedly and consistently been shown to be a predictor of both poor in-hospital outcome and long-term survival.
In a series of 6,359 patients undergoing aortic valve replacement, Hannan et al. showed an incremental increase in the adjusted hazard ratio for 30-month survival from 1.57 to 2.18 to 3.96 in age ranges 65-74 y, 75-84 y and ≥85 y, respectively. After isolated AVR, the 30-month survival was 90.1% for patients of age <75 and 86.2% for patients >75 years of age. 10 A study in octogenarians with severe AS showed that survival rates of 87, 78 and 68%, respectively, compared with 52, 40 and 22%, respectively, in those who had no AVR. 11 Elderly patients on the other hand experience increased operative mortality and also are at higher risk for valve-related events. 12, 13 Nevertheless, age is not, per se, a contraindication to AVR according to published guidelines. 3, 14, 15, 16 Analysis of determinants of operative mortality in regard to age showed that age is not linearly related to the mortality rate after AVR 10,17 and there is considerable functional improvement after valve replacement. 18
Limits related to comorbidity:
Additionally, patients can be refused surgery because of severe comorbidities known to be associated with poor outcome. Since the prevalence of AS increases with age, and as longevity within the general population is increasing, the proportion of patients for whom surgery may be too late due to multiple comorbidities is also expected to increase. These comorbidities may be related to concomitant cardiac diseases which further compromise myocardial function such as poor left ventricular ejection fraction (LVEF), previous cardiac surgery and associated coronary artery disease (CAD). Other comorbidities related to the general condition of the patient such as neurological dysfunction, chronic lung disease, liver cirrhosis and renal
Limits related to presence of concomitant coronary artery disease:
due to the presence of a concomitant cardiac pathology and impaired LV function from an ischaemic myocardium. 12 Patients with acute myocardial infarction (AMI) <24 hours or who were haemodynamically unstable had a risk-adjusted 30-month survival of 59.6%, compared with 83.6% for patients with neither AMI <24 hours nor haemodynamic instability. 10 has changed with patients presenting with several comorbidities particularly CAD, concomitant CABG and a greater incidence of left heart failure. The operative mortality of AVR doubles with the addition of a concomitant CABG procedure which cannot be explained by the simple increment in cross clamping and cardiopulmonary bypass times. 7 Concomitant CABG had an adjusted 30-month mortality hazard ratio of 1.26 in comparison with isolated AVR. After AVR, LV dimensions normalise more quickly in the group with isolated AVR compared to those with concomitant CABG further suggesting that CAD has a negative impact on postoperative myocardial recovery. The operative risk in patients with CAD requiring concomitant cerebrovascular disease, peripheral vascular disease, extensive aortic atherosclerosis, diabetes and renal failure. 10 Nevertheless, there is a consensus that the addition of CABG to AVR slightly improves longterm survival, even in high-risk populations. 22
Limits related to contractile reserve:
Delay in the management of patients with AS may give rise to certain after AVR. When the aortic valve area is less than half of normal, the gradient across the valve becomes important and the increased afterload is associated with concentric myocardial hypertrophy which maintains systolic performance. The EF is decreased because of increased afterload and impaired diastolic function, but contractility is maintained and AVR has an excellent outcome with EF returning to normal values once the afterload excess is removed. 23 However in other patients, hypertrophy fails to normalise wall stress causing the abnormal afterload to reduce ventricular ejection, reducing cardiac output, adding to the heart failure syndrome. 24 This subset of patients with low gradient AS and low EF is known to 
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Nevertheless, age is not, per se, a contraindication to AVR according to published guidelines. 3, 14, 15, 16 Analysis of determinants of operative mortality in regard to age showed that age is not linearly related to the mortality rate after AVR 10,17 and there is considerable functional improvement after valve replacement. 18
Limits related to comorbidity:
Additionally, patients can be refused surgery because of severe comorbidities known to be associated with poor outcome. Since the prevalence of AS increases with age, and as longevity within the general population is increasing, the proportion of patients for whom surgery may be too late due to multiple comorbidities is also expected to increase. These comorbidities may be related to concomitant cardiac diseases which further compromise myocardial function such as poor left ventricular ejection fraction (LVEF), previous cardiac surgery and associated coronary artery disease (CAD). Other comorbidities related to the general condition of the patient such as neurological dysfunction, chronic lung disease, liver cirrhosis and renal These patients are prone to severe postoperative complications as infections and bleeding; and the procedure itself may further compromise vital organ function. 10, 19, 20 The contribution of these factors can increase the odds ratio for operative mortality by a factor of 10.6 for emergency versus elective surgery, 4.9 for renal failure, 3.1 for NYHA class (III-IV versus I-II) and 4.3 for neurological dysfunction.3 Thus it may too late to perform elective valve replacement on patients with terminal end-organ failure of the liver (Child-Pugh class B or C cirrhosis) or lung.
Despite the increased risk with several comorbidities, survival in elderly patients (≥80 years) with severe AS and low LVEF (≤30%) and/ or chronic renal failure was still better in patients who had AVR as compared to those who did not. 11 cer ath con ter 
Limits related to contractile reserve:
Delay in the management of patients with AS may give rise to certain after AVR. When the aortic valve area is less than half of normal, the gradient across the valve becomes important and the increased afterload is associated with concentric myocardial hypertrophy which maintains systolic performance. The EF is decreased because of increased afterload and impaired diastolic function, but contractility is maintained and AVR has an excellent outcome with EF returning to normal values once the afterload excess is removed. 23 However in other patients, hypertrophy fails to normalise wall stress causing the abnormal afterload to reduce ventricular ejection, reducing cardiac output, adding to the heart failure syndrome. 24 This subset of patients with low gradient AS and low EF is known to be associated with poorer outcomes after AVR. It is seen in 5-10% of all cases of severe AS 25 -dient <30 mmHg (or 40 mm Hg), an aortic valve area <1 cm², and an EF<35% (or 40%). 21, 22 In patients with low gradient and low cardiac output, there is severe decrease in EF in excess of what would have occurred through afterload increase alone. 26 The associated myocardial dysfunction contributes to a poor prognosis. Since the transvalvular gradient is small, there is a correspondingly smaller reduction in afterload and thus a smaller improvement in EF following surgery. 27 AVR in this group of patients carries a poor prognosis with an operative mortality reported as high as 21% with a 50% death rate within four years of the procedure. 28 Although AVR is superior to medical management in terms of short-term survival, surgery is not of patients before surgery may decide whether medical or surgical therapy is best.
1) stenosis severity
2) inotropic reserve 3) the presence or absence of CAD or other valve disease, and 4) other comorbidities.
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Patients without inotropic reserve and those with a large increase from AVR and are generally considered a contraindication because of "pseudo-aortic stenosis". Nevertheless, in a recent international multicentre registry of low EF/low gradient AS, AVR was associated with superior survival and was advocated when mean pressure gradient was >20 mm Hg and in the absence of excessive comorbidities or severe CAD with large scarring caused by extensive myocardial infarction. The authors conclude that the lack of contractile reserve in these patients may not systematically be related to irreversible LV dysfunction but probably due to an afterload mismatch that is not corrected by inotropic stimulation with dobutamine infusion. 29
Technical limits to surgical AVR:
In addition to comorbidities, patients may present with technical -form. This is particularly true in patients undergoing redo surgery with patent coronary artery bypass grafts, where the risk of injury to the graft during dissection can be prejudicious to myocardial vascularisation. The matter is further complicated by issues related to cardioplegia when the patent grafts are the internal thoracic arteries. Patients those with previous mediastinal radiotherapy and radiation damage to the myocardium are also known to have poor -matous ascending aorta (porcelain aorta), cross clamping and aortotomy can be impossible.
Since operative mortality is a standard parameter of operative sucThey have been performed via two distinct approaches, namely the transfemoral (TF) and transapical (TA) approaches with established feasibility and have been described in detail. 37, 38, 39 Each approach has its advantages and the selection strategy of patients for one technique or the other depends on centre and physician preference. 40 The decision for performing TAVI is considered in patients with severe symptomatic AS having: 41 • Contraindications to, or high risk for AVR
• Life expectancy >1 year • Favourable anatomy for valve implantation Patients undergo complete clinical examination, transthoracic echocardiography (TTE), TEE, coronary angiography, aortic and femoroiliac angiography and multislice computed tomography prior to surgery. This screening process is necessary to establish feasibility of TAVI and conformity of the aortic root geometry and anatomy. The contraindications for TAVI are listed in Table 1 . Despite opening new horizons for patients refused or contraindicated conventional surgery, several questions remain unanswered concernleaks on survival, and LV function, and the incidence of endocarditis after TAVI. teries. Patients those with previous mediastinal radiotherapy and radiation damage to the myocardium are also known to have poor -matous ascending aorta (porcelain aorta), cross clamping and aortotomy can be impossible.
Since operative mortality is a standard parameter of operative sucgood measure of quality of cardiac surgical care, as long as patient risk factors are taken into consideration, thus several risk scores have been described to calculating predicted operative mortality for patients undergoing cardiac surgery. 30 The most employed surgical scores, namely the EuroSCORE 31 and STS score 32 -titative assessment to establish whether patients are at high risk for this population, these scores do not capture all relevant variables. 15, 33 Moreover they collect a large number of preoperative data that are not all incorporated in the calculation of predicted mortality. Thus out of more than 50 variables collected by the STS score, only 24 are actually used in its mortality algorithm for patients having valve surgery. 15 Variables such as hepatic disease, previous chest wall irradiation, nutritional status and frailty that can STS risk algorithm. 34, 35 Amber et al. described a risk model that can be applied to patients undergoing valve surgery, with or without concomitant CABG surgery based on data from the Great Britain and Ireland national cardiac surgical database. 36 While scores are useful tools to predict operative mortality in a broad sense, clinical judgement and careful preoperative assessment of patients are the key determinants in decision making.
Transcatheter aortic valve implantation (TAVI) techniques
Transcatheter aortic valve implantation (TAVI) techniques have been developed to provide alternative approaches to patients for whom conventional AVR is fraught with a considerable risk (Figure 2 ). These techniques are performed without cardiopulmonary bypass or aortic cross clamping under general or locoregional -raphy (TEE) guidance. ven lea aft They have been performed via two distinct approaches, namely the transfemoral (TF) and transapical (TA) approaches with established feasibility and have been described in detail. 37, 38, 39 Each approach has its advantages and the selection strategy of patients for one technique or the other depends on centre and physician preference. 40
Tab Figure 2: Heavily calcified and atheromatous ascending (porcelain) aorta (arrows). Conventional AVR would be a considerable technical challenge and fraught with hazards. A transcatheter valve has been successfully inserted into the aortic annulus (asterisk).
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Patients undergo complete clinical examination, transthoracic echocardiography (TTE), TEE, coronary angiography, aortic and femoroiliac angiography and multislice computed tomography prior to surgery. This screening process is necessary to establish feasibility of TAVI and conformity of the aortic root geometry and anatomy. The contraindications for TAVI are listed in Table 1 . Despite opening new horizons for patients refused or contraindicated conventional surgery, several questions remain unanswered concernleaks on survival, and LV function, and the incidence of endocarditis after TAVI. They have been performed via two distinct approaches, namely the transfemoral (TF) and transapical (TA) approaches with established feasibility and have been described in detail. 37, 38, 39 Each approach has its advantages and the selection strategy of patients for one technique or the other depends on centre and physician preference. 40
Patients undergo complete clinical examination, transthoracic echocardiography (TTE), TEE, coronary angiography, aortic and femoroiliac angiography and multislice computed tomography prior to surgery. This screening process is necessary to establish feasibility of TAVI and conformity of the aortic root geometry and anatomy. The contraindications for TAVI are listed in Table 1 . Despite opening new horizons for patients refused or contraindicated conventional surgery, several questions remain unanswered concernleaks on survival, and LV function, and the incidence of endocarditis after TAVI.
Aortic regurgitation
In aortic regurgitation (AR), the main strain comes from volume overload on the LV increasing left ventricular work and leading to ventricular remodelling. Initially this allows the heart to cope with the increased load but will eventually lead to the development of heart failure. AVR improves LV function and forward cardiac output and is should be performed before LVEF falls below 50% or when end-systolic dimension increases above 55 mm. It may be too late in patients with extremely dilated LV with depressed LVEF to gain hypertension in patients with severe AR also increases the surgical risk. However, AVR in patients with severe AR and LVEF<40% was medical management. 42 Likewise, AVR in patients with pulmonary hypertension was associated with an acceptable operative risk better (62%) when compared to the conservatively treated group (22%). 43
CONCLUSIONS
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